OTC · Health care

Zomedica Corp. (ZOMDF)

Zomedica Corp. brought in $36.9M of revenue over the twelve months to June 30, 2026, up 30.1% from a year earlier. It posted a net loss of $19M. In fiscal 2025 capital spending exceeded operating cash flow by $18.2M. At June 30, 2026 it held $7.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Watch ZOMDF in 60 seconds

Price

$0.08

-0.89% on the day · September 28, 2026

52-week range $0.06 to $0.16

Market cap

$76.2M

Revenue (last 12 months)

$36.9M

+30.1% year on year

Net margin

-51.4%

What Zomedica Corp. does

Zomedica Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ZOMDF.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$32M	-$84.4M	-$81.9M	-$0.08	-$18.2M
2024	$27.3M	-$51.1M	-$47M	-$0.05	-$28.8M
2023	$25.2M	-$43.3M	-$34.5M	-$0.04	-$27.3M
2022	$18.9M	-$21.9M	-$17M	-$0.02	-$12.5M
2022	$4.1M	-$21.4M	-$18.4M	-$0.06	-$14.4M
2020	$0	-$16.8M	-$16.9M	-$0.06	-$16.3M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 3, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 4, 2025. Not a date the company has announced. See the report calendar

Where ZOMDF ranks in Health care

Revenue$32M

#443 of 742 in Health care · Bottom 40%

Revenue growth+17.4%

#202 of 529 in Health care · Top 38%

Net margin-255.6%

#485 of 541 in Health care · Bottom 10%

Free cash flow margin-56.9%

#384 of 488 in Health care · Bottom 21%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Zomedica Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 5, 2026
Quarterly results 8-K
August 5, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 37% to $9.5M versus the same quarter last year; diluted EPS $0.00 versus -$0.01.
June 11, 2026
Shareholder vote results 8-K
May 6, 2026
Quarterly results 8-K
May 6, 2026
Quarterly report 10-Q · period to March 31, 2026Revenue rose 35% to $8.8M versus the same quarter last year; diluted EPS $0.00 versus -$0.07.
April 27, 2026
Proxy statement DEF 14A
April 24, 2026
Additional proxy material DEFA14A
April 14, 2026
Preliminary proxy statement PRE 14A
March 16, 2026
Quarterly results 8-K
March 16, 2026
Annual report 10-K · period to December 31, 2025Revenue rose 17% to $32M versus the prior year; diluted EPS -$0.08 versus -$0.05.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 7, 2026. Insider transactions on SEC

Insider trades

What the people running Zomedica Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
May 21, 2026	Klass Russell KevinSr. Vice President, Sales	Boughtindirect	104,000	$0.10	$10.7K	Form 4
May 21, 2026	Klass Russell KevinSr. Vice President, Sales	Bought	11,399	$0.11	$1.2K	Form 4
May 21, 2026	Klass Russell KevinSr. Vice President, Sales	Bought	5,500	$0.11	$577.5	Form 4
May 20, 2026	Klass Russell KevinSr. Vice President, Sales	Bought	200,000	$0.11	$21K	Form 4
May 20, 2026	Powers Johnny DDirector	Bought	97,515	$0.10	$10K	Form 4
May 19, 2026	Powers Johnny DDirector	Bought	2,485	$0.10	$256	Form 4
May 18, 2026	Powers Johnny DDirector	Bought	100,000	$0.10	$10.3K	Form 4
May 13, 2026	Powers Johnny DDirector	Bought	200,000	$0.11	$21.2K	Form 4
May 12, 2026	Powers Johnny DDirector	Bought	100,000	$0.11	$10.5K	Form 4
May 11, 2026	Powers Johnny DDirector	Bought	391,129	$0.11	$44.2K	Form 4
May 8, 2026	Powers Johnny DDirector	Bought	108,871	$0.11	$12.2K	Form 4
May 8, 2026	Heaton Larry C IICEO, Director	Bought	250,000	$0.11	$27.5K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ZOMDF

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 16,107,485 shares in total, about $1.3M at the last price.

Holder	Shares	As of
Powers Johnny DDirector	8,752,485	May 20, 2026
Klass Russell KevinSr. Vice President, Sales	6,105,000104,000 held indirectly	May 21, 2026
Heaton Larry C IICEO, Director	1,250,000	May 8, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ZOMDF

What does Zomedica Corp. do?

Zomedica Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ZOMDF.

Is Zomedica Corp. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $19M on revenue of $36.9M.

How much revenue does Zomedica Corp. make?

Over the twelve months to June 30, 2026 Zomedica Corp. reported revenue of $36.9M. That is 30.1% more than a year earlier.

When did Zomedica Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 7, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare ZOMDF with

Compare ZOMDF with any company

Follow ZOMDF

Get an email when Zomedica Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ZOMDF: get an email when it files

Where the numbers come from

Financial figures are the values Zomedica Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.